Plain-English translation of NCT05717712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is a specially designed virus that is injected directly into the tumor. The virus is meant to fight the cancer cells from the inside. This is an early-stage study focused on making sure the treatment is safe and that children's bodies can tolerate it.
Diffuse intrinsic pontine glioma (DIPG) is a serious brain stem tumor that affects children, and current treatment options are very limited. Researchers are exploring whether this medication — which uses a virus to attack cancer cells — could offer a new hope for children with this diagnosis.
You likely qualify if…
You likely don't qualify if…
You will undergo a stereotactic procedure to allow doctors to inject the medication directly into your brain tumor. You will receive multiple injections of the treatment over time as part of the study. The research team will closely monitor you for any side effects or safety concerns throughout the trial, with regular check-ups and blood tests to make sure your body is tolerating the medication well.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Capital Medical University
Enrollment target
~18 participants
Started
January 2023
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
1 Year – 18 Years
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiao Qian, Dr.
Capital Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.